Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

BMY, Pfizer Records Consistent Results In Sub-analysis Of Eliquis Vs. Warfarin

Bristol-Myers Squibb Co. (BMY: Quote) and Pfizer Inc. (PFE: Quote) said the Phase III Aristotle trial of Eliquis in comparison with warfarin for the the prevention of stroke or systemic embolism in nonvalvular atrial fibrillation were consistent with the overall results of the Aristotle trial. Further, the companies said the Eliquis compared with warfarin reduced stroke or systemic embolism, caused fewer major bleeding events, and reduced all-cause mortality in NVAF patients with or without valvular heart disease or VHD.

The Aristotle trial excluded patients with clinically significant mitral stenosis, or a mechanical prosthetic heart valve.

The results of the sub analysis were presented in an oral session today at the ESC Congress 2013 in Amsterdam, The Netherlands.

The subanalysis evaluated Eliquis compared to warfarin in patients with or without other types of VHD, who were eligible for enrollment in the Aristotle

trial, including mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis, tricuspid regurgitation, or valve surgery. 4,808 patients participated in the sub analysis.

Eliquis is an oral inhibitor of blood clotting protein Factor Xa.

Click here to receive FREE breaking news email alerts for Bristol-Myers Squibb Co. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.